home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Webinar on The FDA Drug Approval Process

 
  March 04, 2016  
     
 


Compliance Trainings, Online
2016-03-09


Description :

This web seminar provides an overview of the entire FDA Drug Approval Process. This seminar will cover FDA requirements from discovery.

We will begin by developing a molecule, testing it, going through the IND process, clinical testing and finally the NDA process. We will also discuss IND/NDA submission preparation, in-vitro studies, nonclinical studies and human clinical trials. Also discussed will be the underlying scientific and regulatory principles involved in the entire Drug Development Process. This web seminar will also provide a foundation of knowledge for those who require an understanding of the entire FDA Drug Approval Process.

Areas Covered in the Session :

Understand the FDA drug research requirements

Learn about IND process

Learn about Clinical testing requirements

Learn about NDA process

Learn about in-vitro and nonclinical testing

Who Will Benefit:

Regulatory Affairs Personnel

Quality Personnel

Clinical Personnel

Research Personnel

Manufacturing Personnel

Drug Discovery Personnel

Legal Personnel

 

Personnel who require a general understanding of the FDA Drug Approval Process

 
 
Organized by: Compliance Trainings
Invited Speakers:

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor (www.RegulatoryDoctor.us). As a leading industry speaker, Dr. Lim frequently presents global regulatory and quality compliance topics in various forums and meetings. Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past eight years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA's transparency public meeting in 2009.

 
Deadline for Abstracts: 2016-03-09
 
Registration:

For more information about this event please visit

https://compliancetrainings.com/SiteEngine/ProductDetailView.aspx?id=FDB1781

 

To register this webinar

https://compliancetrainings.com/siteengine/Login.aspx 

E-mail: suzzane.d@compliancetrainings.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.